Results from a late-stage trial of Eli Lilly's experimental weight-loss pill were disappointing, sending shares of the ...

Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...

Pharmaceutical giant Eli Lilly (LLY) has reported second-quarter financial results that beat Wall Street estimates and raised ...

A trial assessing a new daily pill for weight loss has shown that people taking the drug can shed kilos in weeks, potentially ...

At the same time, Trump's hint of a carveout for coming duties on semiconductors boosted tech for a second consecutive day. The Dow Jones Industrial Average (^DJI) gained 0.6%, while the S&P 500 ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...

Eli Lilly, a renowned drug manufacturer, stated that its GLP-1 pill, orforglipron, assisted individuals in reducing 12.4% of their weight following 72 weeks in a late-stage study.The company ...

Eli Lilly shares fell as disappointing data on its new weight-loss pill overshadowed strong growth from the company’s current obesity medicine, which helped drive it to raise its yearly profit and ...

Eli Lilly shares fell after orforglipron's Phase 3 data showed less weight loss than rival drugs, despite a strong Q2 ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Eli Lilly and Company has confirmed it’s selling its 25,000-square-foot manufacturing site in Branchburg. The decision was ...